Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
5 UDP-N-acetyl-alpha-D-galactosamine + beta1-adrenergic receptor
5 UDP + (N-acetyl-alpha-D-galactosaminyl)5-beta1-adrenergic receptor
-
-
-
?
5 UDP-N-acetyl-D-galactosamine + DSTTPAPTTK
5 UDP + N-acetyl-D-galactosaminylated DSTTPAPTTK
erythropoietin T + UDP-Gal
erythropoietin T-nGalNAc + UDP
hCG-beta + UDP-Gal
hCG-beta-nGalNAc + UDP
-
-
-
?
IgA hinge + UDP-Gal
IgA hinge-nGal + UDP
-
-
-
?
IgA hinge + UDP-GalNAc
IgA hinge-nGalNAc + UDP
IgA hinge-4GalNAc + UDP-GalNAc
IgA hinge-nGalNAc + UDP
-
-
-
?
MUC1 + UDP-GalNAc
MUC1-nGalNAc + UDP
MUC1-2GalNAc + UDP-GalNAc
MUC1-nGalNAc + UDP
-
-
-
?
MUC1a' + UDP-GalNAc
MUC1a'-nGalNAc + UDP
-
-
-
?
MUC1b' + UDP-GalNAc
MUC1b'-nGalNAc + UDP
-
-
-
?
MUC2 + UDP-GalNAc
MUC2-nGalNAc + UDP
-
-
-
?
MUC2-6GalNAc + UDP-GalNAc
MUC2-nGalNAc + UDP
-
-
-
?
MUC5AC + UDP-GalNAc
GalNAc-Thr9-MUC5AC + UDP
-
hT2CD, hT2: glycosylation site selection driven by and substrate binding through its catalytic domain, hT10: not catalysed by hT10 because hT10 does not recognize naked peptides
preferred site for glycosylation by hT2 and hT2CD compared to Thr-3, Thr-10 and Thr-13
-
?
MUC5AC glycopeptides + UDP-GalNAc
GalNAc-MUC5AC + UDP
-
hT2: site preference of glycosylation depends on location of pre-existing GalNAc and is mediated by its lectin domain which directs glycosylation 10 residues N- or C-terminal to an extant GalNAc residue and aids site selection only when potential site is N-terminal to an extant GalNAc residue not C-terminal, Thr-9 is no preferred site of glycosylation, hT10: must recognize existing GalNAc residues via its catalytic domain which directs selection to the glycosylation site immediately N-terminal to the present GalNAc,
-
-
?
MUC5AC-13 + UDP-GalNAc
GalNAc-Thr12-MUC5AC-13 + UDP
-
hT10, hT10CD, hT10CD-hT2LD
-
-
?
MUC5AC-13 + UDP-GalNAc
GalNAc-Thr3-MUC5AC-13 + UDP
-
hT2: substrate binding through its catalytic domain, hT10: transfer of only single GalNAc residues
predominant product of hT2 and hT10
-
?
MUC5AC-13 + UDP-GalNAc
GalNAc-Thr9-MUC5AC-13 + UDP
-
hT2, hT2CD: no initial burst phase during catalysis
not preferred by hT2, preferred by hT2CD
-
?
MUC5AC-3 + UDP-GalNAc
GalNAc-Thr13-MUC5AC-3 + UDP
-
hT2: no initial burst phase during catalysis, substrate binding through its catalytic domain, hT10: transfer of only single GalNAc residues
hT2: preferred site for glycosylation, mediated by enhanced product release through lectin domain, hT10: predominant product
-
?
MUC5AC-3 + UDP-GalNAc
GalNAc-Thr2-MUC5AC + UDP
-
hT10CD, hT10CD-hT2LD, hT10: catalysis faster than for MUCAC-9
-
-
?
MUC5AC-3 + UDP-GalNAc
GalNAc-Thr9-MUC5AC-3 + UDP
-
hT2, hT2CD
not preferred by hT2, hT2CD: preferred site for glycosylation, lack of lectin domain in hT2CD results in rate-limiting product release
-
?
MUC5AC-3,13 + UDP-GalNAc
GalNAc-Ser-5-MUC5AC-3,13 + UDP
-
hT2, not catalysed by hT2CD and hT2CD-hT10LD
preferred site by hT2
-
?
MUC5AC-3,13 + UDP-GalNAc
GalNAc-Thr2,12-MUC5AC-3,13 + UDP
-
hT10, hT10CD, hT10CD-hT2LD
-
-
?
MUC5AC-9 + UDP-GalNAc
GalNAc-Thr2-MUC5AC-9 + UDP
-
not catalysed by hT10CD and hT10CD-hT2LD, hT10: catalysis slower than for MUC5AC-3
preferred site of glycosylation by hT10
-
?
MUC7 + UDP-GalNAc
MUC7-nGalNAc + UDP
-
-
-
?
OSM fragment + UDP-Gal
OSM fragment-nGalNAc + UDP
-
-
-
?
UDP-galactose + Muc1 peptide
UDP + galactosyl-Muc1 peptide
UDP-galactose + Muc2 peptide
UDP + galactosyl-Muc2 peptide
UDP-galactose + PTTTPITTTTK
UDP + galactosyl-PTTTPITTTTK
UDP-GalNAc + EA2
GalNAc-EA2 + UDP
ternary complex of ppGalNAcT-2 in crystal structure PDB: 2FFU, UDP-GalNAc binding results in the closed confirmation of loop B which stabilises loop A by binding of loop A (N102) to loop B (R362), EA2 peptide binds in an extended confirmation
binary complex of UDP and ppGalNAcT-2 in crystal structure PDB: 2FFV
-
?
UDP-GalNAc + GAGA(X)3T(X)3AGAGK
UDP + GAGA(X)3(GalNAc)T(X)3AGAGK
-
-
-
?
UDP-GalNAc + GAGA(X)5T(X)5AGAGK
UDP + GAGA(X)5(GalNAc)T(X)5AGAGK
very high correlation between peptide preferences of ppGalNAc T2 and fly orthologue PGANT2 with r(square) = 0.92
-
-
?
UDP-GalNAc + GAGA(X)nT(X)nAGAGK
GAGA(X)n(GalNAc)T(X)nAGAGK + UDP
library of unmodified peptides, with randomized residue at position X and n=3 or n=5, random peptide preferences are not significantly altered by increased peptide substrate length n=5 compared to n=3 or the proximity of flanking Gly and Ala residues to the site of glycosylation, major peptide substrate preference determinants are the 2 to 3 residues flanking the site of glycosylation
-
-
?
UDP-GalNAc + HGVTSAPDTRPAPGSTAPPA
UDP + ?
-
-
-
-
?
UDP-GalNAc + PTTTPISTTTMVTPTPTPTC
UDP + ?
-
-
-
-
?
UDP-GalNAc + VLTTTATTPTA
UDP + ?
-
-
-
-
?
UDP-N-((2S)-2-azidopropanoyl)-alpha-D-galactosamine + peptide EA2-biotin
UDP + N-((2S)-2-azidopropanoyl)-alpha-D-galactosaminyl-peptide EA2-biotin
i.e. PTTDSTTPAPTTKK-biotin
-
-
-
UDP-N-acetyl-alpha-D-galactosamine + (glycosylated GTTPSPVPTTSTTSAP)
UDP + ?
-
natural-type (alpha-GalNAc-O-Thr) and unnatural-type (beta-GalNAc-O-Thr, alpha-Fuc-O-Thr and beta-GlcNAc-O-Thr) glycosylated
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + Ac-CIRIQRGPGRAFVTIGKIGNMR
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + Ac-QATEYEYLDYDFLPETEPPEM
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + AHGVTSAPDTR
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + delta-opioid receptor
UDP + N-acetyl-alpha-D-galactosaminyl-delta-opioid receptor
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GAGAEAPTPAPAGAGK
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTAKPTTLKPTE
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTSTTSAP
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTSTTSAP
UDP + GT[GalNAc]TPSPVPTTSTTSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTSTTSAP
UDP + GT[GalNAc]TPSPVPTTST[GalNAc]TSAP
-
-
glycosylation at Thr-3 and Thr-13
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTSTTSAP
UDP + GT[GalNAc]TP[GalNAc]SPVPTTSTTSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTST[GalNAc]TSAP
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTST[GalNAc]TSAP
UDP + GT[GalNAc]TPSPVPTTST[GalNAc]TSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GTTPSPVPTTST[GalNAc]TSAP
UDP + GT[GalNAc]TP[GalNAc]SPVPTTST[GalNAc]TSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GT[GalNAc]TPSPVPTTSTTSAP
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GT[GalNAc]TPSPVPTTSTTSAP
UDP + GT[GalNAc]TPSPVPTTS[GalNAc]T[GalNAc]TSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GT[GalNAc]TPSPVPTTSTTSAP
UDP + G[GalNAc]T[GalNAc]TPSPVPTTST[GalNAc]TSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + GT[GalNAc]TPSPVPTTST[GalNAc]TSAP
UDP + GT[GalNAc]TPSPVPTTS[GalNAc]T[GalNAc]TSAP
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + human mucin Muc2 peptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + Muc7 peptide
?
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + PDTRPAPGSTAPPAC
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + peptide EA2-biotin
UDP + N-acetyl-alpha-D-galactosaminyl-peptide EA2-biotin
i.e. PTTDSTTPAPTTKK-biotin
-
-
-
UDP-N-acetyl-alpha-D-galactosamine + polypeptide
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide angiopoietin-like 3
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide angiopoietin-like 3
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide EA2
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide EA2
sequence PTTDSTTPAPTTK
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide FGF23
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide FGF23
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide GPIV
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide GPIV
-
preferred substrate for isoforms ppGalNAc T2, T5, T13, T14, and T16
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide GPIV-C
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide GPIV-C
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide GPV
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide GPV
-
preferred substrate for isoforms ppGalNAc T3, T5, T6, T13, and T16
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide GPV-C
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide GPV-C
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide Muc1
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide Muc1
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + polypeptide MUC13
UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide MUC13
-
isoform GALNT14 contributes to the glycosylation of peptide MUC13, which is significantly higher in ovarian cancer cells compared with the normal/benign ovary tissues
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + PSTPPTPSPSTPPTPSPS
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + PTTDSTTPAPTTK
UDP + ?
-
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + SDC106 peptide
?
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + SDC155 peptide
?
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + SDC165 peptide
?
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + SDC284 peptide
?
-
-
-
?
UDP-N-acetyl-alpha-D-galactosamine + SPTTSTPISSTPQPTS
UDP + ?
-
-
-
-
?
UDP-N-acetyl-D-galactosamine + Ac-CIRIQRGPGRAFVTIGKIGNMR
UDP + N-acetyl-D-galactosaminylated Ac-CIRIQRGPGRAFVTIGKIGNMR
-
-
-
?
UDP-N-acetyl-D-galactosamine + Ac-PFVTHPGYD
UDP + N-acetyl-D-galactosaminylated Ac-PFVTHPGYD
-
-
-
?
UDP-N-acetyl-D-galactosamine + Ac-QATEYEYLDYDFLPETEPPEM
UDP + N-acetyl-D-galactosaminylated Ac-QATEYEYLDYDFLPETEPPEM
UDP-N-acetyl-D-galactosamine + AHGVTSAPDTR
UDP + N-acetyl-D-galactosaminylated AHGVTSAPDTR
-
-
-
?
UDP-N-acetyl-D-galactosamine + AHGVVTSAPDTR
UDP + ?
UDP-N-acetyl-D-galactosamine + ANTPSFPTATSPAPPI
UDP + ?
UDP-N-acetyl-D-galactosamine + apomucin
UDP + N-acetyl-D-galactosaminyl-apomucin
-
acceptor: apomucin motif encoded by the MUC5AC gene
-
-
?
UDP-N-acetyl-D-galactosamine + CPPTPSATTPAPPSSSAPPETTAA
UDP + N-acetyl-D-galactosaminylated CPPTPSATTPAPPSSSAPPETTAA
UDP-N-acetyl-D-galactosamine + fibronectin
UDP + N-acetyl-D-galactosaminyl-fibronectin
-
fibronectin is a physiological substrate for GalNAc-T3
-
-
?
UDP-N-acetyl-D-galactosamine + GAGAPGPTPGPAGAGK
UDP + GAGAPGP-(N-acetyl-D-galactosaminylT)-PGPAGAGK
-
optimal isozyme ppGalNAc T2 peptide substrate
-
-
?
UDP-N-acetyl-D-galactosamine + GalNAc-glycosylated peptide
UDP + N-acetyl-D-galactosaminyl-GalNAc-glucosylated peptide
UDP-N-acetyl-D-galactosamine + GTTPSPVPTTSTTSA
UDP + N-acetyl-D-galactosaminyl-[GTTPSPVPTTSTTSA]
i.e. Muc5Ac peptide, multiple possible binding sites for N-acetyl-D-galactosamine on the peptide
-
-
?
UDP-N-acetyl-D-galactosamine + GTTPSPVPTTSTTSAk
UDP + ?
UDP-N-acetyl-D-galactosamine + HIV-V3 peptide
UDP + N-acetyl-D-galactosaminyl-HIV-V3 peptide
UDP-N-acetyl-D-galactosamine + human chorionic gonadotropin-beta peptide
UDP + N-acetyl-D-galactosaminyl-human chorionic gonadotropin-beta peptide
UDP-N-acetyl-D-galactosamine + immunoglobulin A1
UDP + N-acetyl-D-galactosaminyl-immunoglobulin A1
-
O-linked glycosylation of the human IgA1 hinge region by ppGalNAc-T2, synthetic IgA hinge peptide: ppGalNAc-T2 shows strongest activity and is able to transfer GalNAc to almost all possible glycosylation sites, other ppGalNAc-Ts show extremely weak activities
-
-
?
UDP-N-acetyl-D-galactosamine + osteopontin
UDP + N-acetyl-D-galactosaminyl-osteopontin
-
isozyme ppGalNAc T10 prefers previously glycosylated peptides as substrates, ppGalNAc T10 exhibits a single large preference for Ser/Thr-O-GalNAc at the +1, C-terminal, position relative to the Ser or Thr acceptor site
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
UDP-N-acetyl-D-galactosamine + PRFQDSSSSKAPPPSLPSPSRL
UDP + N-actetyl-D-galactosaminylated PRFQDSSSSKAPPPSLPSPSRL
-
-
-
?
UDP-N-acetyl-D-galactosamine + PRFQDSSSSKAPPPSLPSPSRLPG
UDP + N-acetyl-D-galactosaminylated PRFQDSSSSKAPPPSLPSPSRLPG
-
-
-
?
UDP-N-acetyl-D-galactosamine + PTTDSTTPAPTT
UDP + ?
UDP-N-acetyl-D-galactosamine + PTTTPISTTMVTPTPTPTC
UDP + N-actetyl-D-galactosaminylated PTTTPISTTMVTPTPTPTC
-
-
-
?
UDP-N-acetyl-D-galactosamine + PTTTPISTTTMVTPTPTPTC
UDP + N-acetyl-D-galactosaminylated PTTTPISTTTMVTPTPTPTC
mucin derived substrate
-
-
?
UDP-N-acetyl-D-galactosamine + PTTTPITTTTTVTPTPTPTGTQT
UDP + ?
UDP-N-acetyl-D-galactosamine + QATEYEYLDYDFLPEC
UDP + N-acetyl-D-galactosaminylated QATEYEYLDYDFLPEC
-
-
-
?
UDP-N-acetyl-D-galactosamine + RPAPGSTAPPA
UDP + N-acetyl-D-galactosaminylated RPAPGSTAPPA
-
-
-
?
UDP-N-acetyl-D-galactosamine + syndecan-3
UDP + N-acetyl-D-galactosaminyl-syndecan-3
syndecan-3 may be a natural substrate for GalNAc-T13
-
-
?
UDP-N-acetyl-D-galactosamine + TAPPAHGVTSAPDTRPAPGSTAPP
UDP + N-acetyl-D-galactosaminylated TAPPAHGVTSAPDTRPAPGSTAPP
UDP-N-hex-5-ynoyl-alpha-D-galactosamine + peptide EA2-biotin
UDP + N-hex-5-ynoyl-alpha-D-galactosaminyl-peptide EA2-biotin
i.e. PTTDSTTPAPTTKK-biotin
-
-
-
additional information
?
-
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
mucin-type O-linked glycosylation of serine or threonine residues
-
-
?
5 UDP-N-acetyl-D-galactosamine + DSTTPAPTTK
5 UDP + N-acetyl-D-galactosaminylated DSTTPAPTTK
mucin derived substrate
-
-
?
5 UDP-N-acetyl-D-galactosamine + DSTTPAPTTK
5 UDP + N-acetyl-D-galactosaminylated DSTTPAPTTK
mucin derived substrate, acceptor substrate
-
-
?
erythropoietin T + UDP-Gal
erythropoietin T-nGalNAc + UDP
-
-
-
?
erythropoietin T + UDP-Gal
erythropoietin T-nGalNAc + UDP
also catalysed by mutants GalTNAc-T2-D458H and GalTNAc-T2-D541A
-
-
?
IgA hinge + UDP-GalNAc
IgA hinge-nGalNAc + UDP
-
-
-
?
IgA hinge + UDP-GalNAc
IgA hinge-nGalNAc + UDP
GalTNAc-T11 incorporates only two GalNAc residues into IgA hinge peptide
-
-
?
IgA hinge + UDP-GalNAc
IgA hinge-nGalNAc + UDP
mutant GalNAc-T2-D458H incorporates 1-2 fewer GalNAc residues than wild-type
-
-
?
MUC1 + UDP-GalNAc
MUC1-nGalNAc + UDP
-
-
-
?
MUC1 + UDP-GalNAc
MUC1-nGalNAc + UDP
GalNAc-T4 lectin domain does not exhibit selective specificities for peptide sequences, or the density or pattern of GalNAc glycosylation, GalNAc-T4 lectin domain mediates GalNAc-glycopeptide substrate specificity
-
-
?
MUC1 + UDP-GalNAc
MUC1-nGalNAc + UDP
mutant GalNAc-T2-D458H incorporates 1-2 fewer GalNAc residues than wild-type, GalNAc-T2 lectin domain does not exhibit selective specificities for peptide sequences, or the density or pattern of GalNAc glycosylation
-
-
?
UDP-galactose + Muc1 peptide
UDP + galactosyl-Muc1 peptide
-
synthetic substrate
-
?
UDP-galactose + Muc1 peptide
UDP + galactosyl-Muc1 peptide
-
2 of 3 threonine residues on the Muc1 tandem repeat peptides, none of the serine residues, maximum is 2 Mol of GalNAc linked to each 20-residue repeat unit
-
?
UDP-galactose + Muc2 peptide
UDP + galactosyl-Muc2 peptide
-
peptides derived of Muc2 mucin
-
-
?
UDP-galactose + Muc2 peptide
UDP + galactosyl-Muc2 peptide
-
only GalNAc-T2, only with the Muc2 acceptor peptide
-
-
?
UDP-galactose + Muc2 peptide
UDP + galactosyl-Muc2 peptide
-
investigation of preferences for distinct threonine residues in the peptide sequences
-
-
?
UDP-galactose + PTTTPITTTTK
UDP + galactosyl-PTTTPITTTTK
-
Muc2 peptide, investigation of preferences for distinct threonine residues in the peptide sequences of isozyme T1 to T4
-
-
?
UDP-galactose + PTTTPITTTTK
UDP + galactosyl-PTTTPITTTTK
-
linked to FITC
-
-
?
UDP-N-acetyl-D-galactosamine + Ac-QATEYEYLDYDFLPETEPPEM
UDP + N-acetyl-D-galactosaminylated Ac-QATEYEYLDYDFLPETEPPEM
-
-
-
?
UDP-N-acetyl-D-galactosamine + Ac-QATEYEYLDYDFLPETEPPEM
UDP + N-acetyl-D-galactosaminylated Ac-QATEYEYLDYDFLPETEPPEM
acceptor substrate
-
-
?
UDP-N-acetyl-D-galactosamine + AHGVVTSAPDTR
UDP + ?
i.e. Muc1, 3% of the activity with Muc5AC as substrate, enzyme form pp-GalNAc-T2
-
-
?
UDP-N-acetyl-D-galactosamine + AHGVVTSAPDTR
UDP + ?
i.e. Muc1a, enzyme form pp-GalNAc-T15
-
-
?
UDP-N-acetyl-D-galactosamine + ANTPSFPTATSPAPPI
UDP + ?
i.e. Muc13, about 25% of the activity with Muc5AC as substrate, enzyme form pp-GalNAc-T2
-
-
?
UDP-N-acetyl-D-galactosamine + ANTPSFPTATSPAPPI
UDP + ?
i.e. Muc13, about 50% of the activity with Muc1a, enzyme form pp-GalNAc-T15
-
-
?
UDP-N-acetyl-D-galactosamine + CPPTPSATTPAPPSSSAPPETTAA
UDP + N-acetyl-D-galactosaminylated CPPTPSATTPAPPSSSAPPETTAA
mucin derived substrate
-
-
?
UDP-N-acetyl-D-galactosamine + CPPTPSATTPAPPSSSAPPETTAA
UDP + N-acetyl-D-galactosaminylated CPPTPSATTPAPPSSSAPPETTAA
mucin derived substrate, acceptor substrate
-
-
?
UDP-N-acetyl-D-galactosamine + GalNAc-glycosylated peptide
UDP + N-acetyl-D-galactosaminyl-GalNAc-glucosylated peptide
GalNAc-T7: exclusive specificity for partially GalNAc-glycosylated acceptor substrates, GalNAc-glycosylated peptide substrates derived from the tandem repeats of human Muc2 and rat submandibular gland mucin, specificity of GalNAc-T4
-
-
?
UDP-N-acetyl-D-galactosamine + GalNAc-glycosylated peptide
UDP + N-acetyl-D-galactosaminyl-GalNAc-glucosylated peptide
-
rGalNAc-T4 is dependent on the presence of GalNAc on acceptor peptides, activity is triggered by a lectin-like interaction of enzyme with the glycopeptide directed by the putative lectin domain found in the C-terminal region, rGalNAc-T2 activity is enhanced on glycosylated acceptor peptides
-
-
?
UDP-N-acetyl-D-galactosamine + GalNAc-glycosylated peptide
UDP + N-acetyl-D-galactosaminyl-GalNAc-glucosylated peptide
-
ppGalNAc-T14 can utilize GalNAc transferred peptides as substrates
-
-
?
UDP-N-acetyl-D-galactosamine + GalNAc-glycosylated peptide
UDP + N-acetyl-D-galactosaminyl-GalNAc-glucosylated peptide
-
ppGalNAc-T4 and -T7 prefer peptides having GalNAc residues as acceptor substrates
-
-
?
UDP-N-acetyl-D-galactosamine + GalNAc-glycosylated peptide
UDP + N-acetyl-D-galactosaminyl-GalNAc-glucosylated peptide
-
acceptors: partially glycosylated versions of a peptide derived from mucin2, pp-GalNAc-T1, -T2, -T3 and -T4 exhibit distinct specificities toward glycopeptides, pathway of incorporation of the second and third GalNAc, isoenzymes may recognize directly GalNAc residues in the vicinity
-
-
?
UDP-N-acetyl-D-galactosamine + GTTPSPVPTTSTTSAk
UDP + ?
i.e. Muc5AC, about 55% of the activity with Muc1a, pp-GalNAc-T15 shows significantly less catalytic activity than pp-GalNAc-T2,T15 transferrs up to seven GalNAcs to the Muc5AC peptide, while T2 transferrs up to five GalNAcs, enzyme form pp-GalNAc-T15
-
-
?
UDP-N-acetyl-D-galactosamine + GTTPSPVPTTSTTSAk
UDP + ?
i.e. Muc5AC, pp-GalNAc-T15 shows significantly less catalytic activity than pp-GalNAc-T2,T15 transferrs up to seven GalNAcs to the Muc5AC peptide, while T2 transferrs up to five GalNAcs
-
-
?
UDP-N-acetyl-D-galactosamine + HIV-V3 peptide
UDP + N-acetyl-D-galactosaminyl-HIV-V3 peptide
-
HIVIIIBgp120, only GalNAc-T3
-
-
?
UDP-N-acetyl-D-galactosamine + HIV-V3 peptide
UDP + N-acetyl-D-galactosaminyl-HIV-V3 peptide
-
placenta, but not liver enzyme
-
-
?
UDP-N-acetyl-D-galactosamine + human chorionic gonadotropin-beta peptide
UDP + N-acetyl-D-galactosaminyl-human chorionic gonadotropin-beta peptide
-
placenta enzyme
-
-
?
UDP-N-acetyl-D-galactosamine + human chorionic gonadotropin-beta peptide
UDP + N-acetyl-D-galactosaminyl-human chorionic gonadotropin-beta peptide
-
only Ser acceptor sites, with a very low activity
-
-
?
UDP-N-acetyl-D-galactosamine + human chorionic gonadotropin-beta peptide
UDP + N-acetyl-D-galactosaminyl-human chorionic gonadotropin-beta peptide
-
only GalNAc-T2
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
-
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
ppGalNAc-T14: acceptors are mucin-derived peptides such as Muc2, Muc5AC, Muc7, Muc13
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
ppGalNAc-T13: acceptors are mucin peptides, such as Muc1a', Muc5Ac and Muc7, forms a triplet Tn epitope, 3 consecutive GalNAc-Ser/Thr structures, on peptides encoded in syndecan-3, different substrate specificities of ppGalNAc-T1 and -T13
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
substrate specificities of recombinant ppGalNAc-T1, -T2, -T3, -T4, -T6 and T9
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
site-specific O-glycosylation by rGalNAc-T2 and -T4 is controlled by the primary sequence context and the position and structure of previously introduced O-glycans, acceptors: synthetic mucin-type peptides and glycopeptides derived from tandem repeat regions of MUC1, MUC2 and MUC4, minimum peptide length is required, which is larger for glycosylated substrates, concerted and sequential action of rGalNAc-T2 and -T4 fully glycosylates MUC1, but only partially MUC2 and MUC4 tandem repeat peptides
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
acceptor specificity
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
GalNAc-T1 and -T3: strict specificity for UDP-GalNAc, GalNAc-T2: utilizes UDP-GalNAc and UDP-Gal
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
acceptor: mucin2 derived fluorescein-conjugated peptide Pro-Thr-Thr-Thr-Pro-Leu-Lys, preferential sites of O-glycosylation by pp-GalNAc-T1, -T2, -T3 and -T4, of which each has a unique specificity
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
acceptor: human MUC5AC peptide Thr-Thr-Ser-Ala-Pro-Thr-Thr-Ser
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
transfer of GalNAc to a serine or threonine residue on the acceptor protein
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
acceptors: human mucin Muc1 and Muc2 peptides, human chorionic gonadotropin-beta peptide, HIV-V3 peptides
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
3 GalNAc-transferases: GalNAc-T1, -T2 and -T3 with distinct but partly overlapping specificities, dependent on the primary sequence of the acceptor substrate, acceptors: peptides based on Muc1 tandem repeat, TAP24, Muc2, Muc5AC, erythropoietin, hCG-beta, HIVIIIBgp120, ovine submaxillary mucin fragment, peptide derived from fibronectin, GalNAc-T1, -T2 and -T3 react at different rates with individual sites in the Muc1 repeat
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
ppGalNAc-T13: synthesis of O-glycan, specifically the Tn antigen in neurons
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
GalNAc-T7: functions as a follow-up enzyme in the initiation step of O-glycosylation
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
initiation of mucin-type O-glycosylation by a family of polypeptide GalNAc-transferases, of which each has a unique function
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
initiation of mucin-type O-glycosylation by a family of polypeptide GalNAc-transferases, of which each has a unique function
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
different enzyme activities are involved in the initiation of GalNAc O-glycosylation and these are differentially expressed in cells and organs
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
ppGalNAc-T14 may be involved in O-glycosylation in kidney
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
catalyzes the first step in biosynthesis of O-linked oligosaccharides in many glycoproteins
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
GalNAc-T9 catalyzes O-glycosylation in brain
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
post-translational, initial reaction in O-linked oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
ppGalNAc-T2: initiation of O-glycosylation in the IgA1 hinge region
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
primary step in the production of mucin-type O-linked oligosaccharide groups in glycoproteins
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
the enzyme is involved in the normal development of the brain through O-glycosylation of proteins in the neurons
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
mucin-type O-linked glycosylation of serine or threonine residues
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
mucin-type O-linked glycosylation of serine or threonine residues
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
mucin-type O-linked glycosylation of serine or threonine residues
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
mucin-type O-linked glycosylation of serine or threonine residues
-
-
?
UDP-N-acetyl-D-galactosamine + polypeptide
UDP + N-acetyl-D-galactosaminyl-polypeptide
-
usage of random peptide substrates, overview. Isozyme substrate specificities, amino acid residue enhancement factors for ppGalNAc T isozymes are obtained from random peptide substrates, detailed overview
product analysis by NMR and mass spectrometry
-
?
UDP-N-acetyl-D-galactosamine + PTTDSTTPAPTT
UDP + ?
i.e. EA2, about 25% of the activity with Muc1a, enzyme form pp-GalNAc-T15
-
-
?
UDP-N-acetyl-D-galactosamine + PTTDSTTPAPTT
UDP + ?
i.e. EA2, about 35% of the activity with Muc5AC as substrate, enzyme form pp-GalNAc-T2
-
-
?
UDP-N-acetyl-D-galactosamine + PTTTPITTTTTVTPTPTPTGTQT
UDP + ?
i.e. Muc2, about 35% of the activity with Muc1a, enzyme form pp-GalNAc-T15
-
-
?
UDP-N-acetyl-D-galactosamine + PTTTPITTTTTVTPTPTPTGTQT
UDP + ?
i.e. Muc2, about 95% of the activity with Muc5AC as substrate, enzyme form pp-GalNAc-T2
-
-
?
UDP-N-acetyl-D-galactosamine + TAPPAHGVTSAPDTRPAPGSTAPP
UDP + N-acetyl-D-galactosaminylated TAPPAHGVTSAPDTRPAPGSTAPP
-
-
-
?
UDP-N-acetyl-D-galactosamine + TAPPAHGVTSAPDTRPAPGSTAPP
UDP + N-acetyl-D-galactosaminylated TAPPAHGVTSAPDTRPAPGSTAPP
acceptor substrate
-
-
?
additional information
?
-
GalNAc-T7: no activity with non-glycosylated peptides and GalNAc-glycosylated Muc1 substrate
-
-
?
additional information
?
-
-
GalNAc-T7: no activity with non-glycosylated peptides and GalNAc-glycosylated Muc1 substrate
-
-
?
additional information
?
-
-
different substrate specificities before and after Muc2 affinity chromatography of enzyme
-
-
?
additional information
?
-
-
multiple enzyme isoforms
-
-
?
additional information
?
-
-
multiple enzyme isoforms
-
-
?
additional information
?
-
-
multiple enzyme isoforms
-
-
?
additional information
?
-
multiple enzyme isoforms
-
-
?
additional information
?
-
-
multiple enzyme isoforms
-
-
?
additional information
?
-
-
multiple enzyme isoforms
-
-
?
additional information
?
-
multiple enzyme isoforms
-
-
?
additional information
?
-
-
multiple enzyme isoforms
-
-
?
additional information
?
-
-
14 distinct isoforms different with regard to their expression and specificity, but overlaps also occur, ppGalNAc-T14 forms together with ppGalNAc-T2 a subfamily of ppGalNAc-T gene family
-
-
?
additional information
?
-
-
all known rGalNAc-Ts are characterized by a putative lectin domain in their C-terminal regions
-
-
?
additional information
?
-
-
GalNAc-T9 contains a 485-amino acid putative catalytic region, GalNAc-T1, -T2, -T4 and -T8 belongs to the housekeeping enzymes with ubiquitous expression, GalNAc-T3, -T5, -T6, -T7 and -T9 belongs to the tissue-specific enzymes
-
-
?
additional information
?
-
-
existence of multiple enzyme activities, differentially expressed in different organs, at least 2 distinct enzyme specificities
-
-
?
additional information
?
-
-
at least 11 human ppGalNAc-Ts
-
-
?
additional information
?
-
-
not: UDP-GlcNAc
-
-
?
additional information
?
-
-
amino acid sequences of seven GalNAc-transferases
-
-
?
additional information
?
-
amino acid sequences of seven GalNAc-transferases
-
-
?
additional information
?
-
-
amino acid sequences of seven GalNAc-transferases
-
-
?
additional information
?
-
-
pp-GalNAc-T13 is specifically expressed in neurons and synthesizes Tn antigen
-
-
?
additional information
?
-
pp-GalNAc-T13 is specifically expressed in neurons and synthesizes Tn antigen
-
-
?
additional information
?
-
MUC1-2GalNAc, MUC2-6GalNAc, OSM fragments, hCG-beta are not substrates for GalNAc-T11
-
-
?
additional information
?
-
MUC1-2GalNAc, MUC2-6GalNAc, OSM fragments, hCG-beta are not substrates for GalNAc-T11
-
-
?
additional information
?
-
MUC1-2GalNAc, MUC2-6GalNAc, OSM fragments, hCG-beta are not substrates for GalNAc-T11
-
-
?
additional information
?
-
MUC1-2GalNAc, MUC2-6GalNAc, OSM fragments, hCG-beta are not substrates for GalNAc-T11
-
-
?
additional information
?
-
MUC1b' and hCG-beta are no substrates for GalNAc-T1
-
-
?
additional information
?
-
MUC1b' and hCG-beta are no substrates for GalNAc-T1
-
-
?
additional information
?
-
MUC1b' and hCG-beta are no substrates for GalNAc-T1
-
-
?
additional information
?
-
MUC1b' and hCG-beta are no substrates for GalNAc-T1
-
-
?
additional information
?
-
-
UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases transfer GalNAc from UDP-GalNAc to the Ser and Thr residues of polypeptide acceptors, and initiate and regulate mucin-type O-glycosylation
-
-
?
additional information
?
-
-
most active with partially glycosylated MUC5AC (by a combination of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 and UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2)
-
-
?
additional information
?
-
-
no activity observed with substrate peptides of other UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases
-
-
?
additional information
?
-
no activity toward classical substrates
-
-
?
additional information
?
-
no activity with 2'-deoxy-alpha-D-galactosamine or 2'-oxymethyl-alpha-D-galactosamine
-
-
?
additional information
?
-
-
no activity with 2'-deoxy-alpha-D-galactosamine or 2'-oxymethyl-alpha-D-galactosamine
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.
Adenocarcinoma
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Adenocarcinoma
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Adenocarcinoma
Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines.
Adenocarcinoma
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma.
Adenocarcinoma
Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas.
Adenocarcinoma
GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (??3 cm).
Adenocarcinoma
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Adenocarcinoma
N-acetylgalactosaminyltransferase: a potential target for colorectal adenocarcinoma.
Adenocarcinoma
Structural basis for the regulation of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells.
Adenocarcinoma
The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Adenocarcinoma of Lung
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Adenocarcinoma of Lung
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
Adenocarcinoma of Lung
GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
Adenocarcinoma of Lung
KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Adenocarcinoma of Lung
Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection.
Adenocarcinoma, Mucinous
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Adenoma
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome.
Anemia, Sickle Cell
Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).
Atherosclerosis
Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis.
Atherosclerosis
Identification of CAD candidate genes in GWAS loci and their expression in vascular cells.
Brain Neoplasms
Glycosyltransferase activities in human meningiomas. Preliminary results.
Breast Neoplasms
An anti-human ppGalNAcT-2 monoclonal antibody.
Breast Neoplasms
Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells.
Breast Neoplasms
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Breast Neoplasms
EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion.
Breast Neoplasms
Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination.
Breast Neoplasms
Estrogen Regulates Vesicle Trafficking Gene Expression in EFF-3, EFM-19 and MCF-7 Breast Cancer Cells.
Breast Neoplasms
GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells.
Breast Neoplasms
GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells.
Breast Neoplasms
GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
Breast Neoplasms
GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment.
Breast Neoplasms
GALNT3 Maintains the Epithelial State in Trophoblast Stem Cells.
Breast Neoplasms
Glycosyltransferases as Markers for Early Tumorigenesis.
Breast Neoplasms
LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity.
Breast Neoplasms
Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression.
Breast Neoplasms
Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown.
Breast Neoplasms
N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
Breast Neoplasms
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
Breast Neoplasms
Osterix Decreases the Chemosensitivity of Breast Cancer Cells by Upregulating GALNT14.
Breast Neoplasms
Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.
Breast Neoplasms
p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene.
Breast Neoplasms
ppGalNAc-T4-catalyzed O-Glycosylation of TGF-? type ? receptor regulates breast cancer cells metastasis potential.
Breast Neoplasms
Prognostic utility of glycosyltransferase expression in breast cancer.
Breast Neoplasms
Reduced expression of ppGalNAc-T4 promotes proliferation of human breast cancer cells.
Breast Neoplasms
RNA interference-mediated silencing of ppGalNAc-T1 and ppGalNAc-T2 inhibits invasion and increases chemosensitivity potentially by reducing terminal ?2,3 sialylation and MMP14 expression in triple?negative breast cancer cells.
Breast Neoplasms
The Role for GALNT14 in the lung metastasis of breast cancer.
Breast Neoplasms
The role of ppGalNAc-T family in breast cancer development and progression.
Breast Neoplasms
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Breast Neoplasms
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.
Calcinosis
A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Calcinosis
A Cross-Sectional Cohort Study of the Effects of FGF23 Deficiency and Hyperphosphatemia on Dental Structures in Hyperphosphatemic Familial Tumoral Calcinosis.
Calcinosis
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
Calcinosis
A Mouse with an N-Ethyl-N-Nitrosourea (ENU) Induced Trp589Arg Galnt3 Mutation Represents a Model for Hyperphosphataemic Familial Tumoural Calcinosis.
Calcinosis
A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.
Calcinosis
A novel homozygous variant in exon 10 of the GALNT3 gene causing hyperphosphatemic familial tumoral calcinosis in a family from North India.
Calcinosis
Ablation of the Galnt3 gene leads to low circulating intact Fgf23 concentrations and hyperphosphatemia despite increased Fgf23 expression.
Calcinosis
Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis.
Calcinosis
Association of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture study.
Calcinosis
Bone Involvement in Hyperphosphatemic Familial Tumoral Calcinosis: A New Phenotypic Presentation.
Calcinosis
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Calcinosis
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Calcinosis
Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.
Calcinosis
Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.
Calcinosis
GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis.
Calcinosis
GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Calcinosis
Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Calcinosis
Giantin-knockout models reveal a feedback loop between Golgi function and glycosyltransferase expression.
Calcinosis
Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.
Calcinosis
Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
Calcinosis
Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey
Calcinosis
Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation: Transient Response to Anti-Interleukin-1 Treatments.
Calcinosis
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
Calcinosis
Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Calcinosis
Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Calcinosis
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Calcinosis
Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and ?Klotho).
Calcinosis
Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.
Calcinosis
Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.
Calcinosis
Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.
Calcinosis
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Calcinosis
Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.
Calcinosis
Novel Regulators of Phosphate Homeostasis and Bone Metabolism.
Calcinosis
Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
Calcinosis
Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.
Calcinosis
Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
Calcinosis
Reply to ultrastructural study of the clinically uninvolved skin in familial tumoral calcinosis caused by mutations in GALNT3.
Calcinosis
Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
Calcinosis
The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Calcinosis
Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family.
Calcinosis
Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Calcinosis
Two novel GALNT3 mutations in familial tumoral calcinosis.
Calcinosis
Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis.
Calcinosis
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]
Calcinosis
[Tumoral calcinosis]
Carcinogenesis
Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis.
Carcinogenesis
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.
Carcinogenesis
Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.
Carcinogenesis
GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells.
Carcinogenesis
GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.
Carcinogenesis
GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of ?2M.
Carcinogenesis
GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition.
Carcinogenesis
Molecular profiling of chordoma.
Carcinogenesis
Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth.
Carcinogenesis
Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.
Carcinogenesis
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome.
Carcinogenesis
Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis.
Carcinogenesis
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Carcinogenesis
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
Carcinogenesis
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
Carcinogenesis
The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling.
Carcinogenesis
The polypeptide N-acetylgalactosaminyltransferase 4 exhibits stage-dependent expression in colorectal cancer and affects tumorigenesis, invasion and differentiation.
Carcinogenesis
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Carcinoma
An anti-human ppGalNAcT-2 monoclonal antibody.
Carcinoma
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Carcinoma
Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Carcinoma
Erratum to: Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Carcinoma
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Carcinoma
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Carcinoma
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Carcinoma
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Carcinoma
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.
Carcinoma
Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.
Carcinoma
GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.
Carcinoma
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Carcinoma
GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Carcinoma
GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.
Carcinoma
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Carcinoma
Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis.
Carcinoma
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Carcinoma
Molecular cloning of the human beta1,4 N-acetylgalactosaminyltransferase responsible for the biosynthesis of the Sd(a) histo-blood group antigen: the sequence predicts a very long cytoplasmic domain.
Carcinoma
Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
Carcinoma
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
Carcinoma
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
Carcinoma
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.
Carcinoma
ppGalNAc T1 as a potential novel marker for human bladder cancer.
Carcinoma
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Carcinoma
Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma.
Carcinoma
Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype.
Carcinoma
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Carcinoma
Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells.
Carcinoma
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
Carcinoma
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Carcinoma, Ductal
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Carcinoma, Embryonal
Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation.
Carcinoma, Embryonal
CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C.
Carcinoma, Endometrioid
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Carcinoma, Hepatocellular
A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.
Carcinoma, Hepatocellular
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
Exosome-derived SNHG16 sponging miR-4500 activates HUVEC angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Carcinoma, Hepatocellular
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Carcinoma, Hepatocellular
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
Carcinoma, Hepatocellular
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Carcinoma, Hepatocellular
GALNT14 genotype, ?-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Carcinoma, Hepatocellular
Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons.
Carcinoma, Hepatocellular
Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.
Carcinoma, Hepatocellular
Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Carcinoma, Intraductal, Noninfiltrating
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Carcinoma, Medullary
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Carcinoma, Non-Small-Cell Lung
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Carcinoma, Non-Small-Cell Lung
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Carcinoma, Non-Small-Cell Lung
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
miR-365b regulates the development of non-small cell lung cancer via GALNT4.
Carcinoma, Ovarian Epithelial
Altered expression of different GalNAc?transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Carcinoma, Ovarian Epithelial
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
Carcinoma, Ovarian Epithelial
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
Carcinoma, Ovarian Epithelial
Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Carcinoma, Ovarian Epithelial
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Carcinoma, Ovarian Epithelial
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
Carcinoma, Papillary
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Carcinoma, Renal Cell
Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.
Carcinoma, Renal Cell
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Carcinoma, Signet Ring Cell
Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype.
Carcinoma, Squamous Cell
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Carcinoma, Squamous Cell
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
Carcinoma, Squamous Cell
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
Cholangiocarcinoma
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
Cholangiocarcinoma
miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling.
Chordoma
Molecular profiling of chordoma.
Colonic Neoplasms
Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
Colonic Neoplasms
MiR-4262 promotes cell apoptosis and inhibits proliferation of colon cancer cells: involvement of GALNT4.
Colonic Neoplasms
miR?4262 inhibits colon cancer cell proliferation via targeting of GALNT4.
Colonic Neoplasms
Polypeptide-GalNAc-T6 expression predicts better overall survival in patients with colon cancer.
Colorectal Neoplasms
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Colorectal Neoplasms
Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer.
Colorectal Neoplasms
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.
Colorectal Neoplasms
Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas.
Colorectal Neoplasms
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma.
Colorectal Neoplasms
GALNT12 is not a major contributor of familial colorectal cancer type X.
Colorectal Neoplasms
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Colorectal Neoplasms
Inherited deleterious variants in GALNT12 are associated with CRC susceptibility.
Colorectal Neoplasms
Intracellular inhibition of blood group A glycosyltransferase.
Colorectal Neoplasms
LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1.
Colorectal Neoplasms
miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
Colorectal Neoplasms
Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3.
Colorectal Neoplasms
The polypeptide N-acetylgalactosaminyltransferase 4 exhibits stage-dependent expression in colorectal cancer and affects tumorigenesis, invasion and differentiation.
Colorectal Neoplasms
The structure of the colorectal cancer-associated enzyme GalNAc-T12 reveals how nonconserved residues dictate its function.
Colorectal Neoplasms, Hereditary Nonpolyposis
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Clinical Utility Gene Card For: GALNT3 defective congenital disorder of glycosylation.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.
Coronary Artery Disease
Genetic polymorphisms in platelet-related proteins and coronary artery disease: investigation of candidate genes, including N-acetylgalactosaminyltransferase 4 (GALNT4) and sulphotransferase 1A1/2 (SULT1A1/2).
Coronary Artery Disease
Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network.
Coronary Artery Disease
Variant in GALNT3 Gene Linked with Reduced Coronary Artery Disease Risk in Chinese Population.
Coronary Disease
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
Cysts
Cyst wall synthase: N-acetylgalactosaminyltransferase activity is induced to form the novel N-acetylgalactosamine polysaccharide in the Giardia cyst wall.
Cysts
Making Home Sweet and Sturdy: Toxoplasma gondii ppGalNAc-Ts Glycosylate in Hierarchical Order and Confer Cyst Wall Rigidity.
De Lange Syndrome
Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation.
Diabetes Mellitus
Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Diabetes Mellitus, Type 1
IDDM7 links to insulin-dependent diabetes mellitus in Danish multiplex families but linkage is not explained by novel polymorphisms in the candidate gene GALNT3. The Danish Study Group of Diabetes in Childhood and The Danish IDDM Epidemiology and Genetics Group.
Diabetes Mellitus, Type 2
GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia.
Diabetes Mellitus, Type 2
Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Diabetes, Gestational
Maternal GALNT2 Variations Affect Blood Pressure, Atherogenic Index, and Fetal Growth, Depending on BMI in Gestational Diabetes Mellitus.
Dry Eye Syndromes
Expression in human ocular surface tissues of the GalNAc-transferases that initiate mucin-type O-glycosylation.
Dwarfism
Overexpression of Galnt3 in chondrocytes resulted in dwarfism due to the increase of mucin-type O-glycans and reduction of glycosaminoglycans.
Dyslipidemias
GALNT2 effect on HDL-cholesterol and triglycerides levels in humans: Evidence of pleiotropy?
Dyslipidemias
Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.
Dyslipidemias
Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells.
Dyslipidemias
The Multiplicity of Polypeptide GalNAc-Transferase: Assays, Inhibitors and Structures.
Endometrial Hyperplasia
Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Endometrial Neoplasms
Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer.
Endometrial Neoplasms
GalNAc-T6 in the relationship with invasion ability of endometrial carcinomas and prognostic significance.
Endometrial Neoplasms
Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.
Endometriosis
Correlation of polypeptide N-acetylgalactosamine transferases-3 and -6 to different stages of endometriosis.
Esophageal Squamous Cell Carcinoma
GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.
Eye Diseases
Autosomal recessive non-syndromic keratoconus: Homozygous frameshift variant in the candidate novel gene GALNT14.
Familial Hypophosphatemic Rickets
The Multiplicity of Polypeptide GalNAc-Transferase: Assays, Inhibitors and Structures.
Gastrointestinal Neoplasms
Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.
Genetic Diseases, Inborn
A sequence-coupled vector-projection model for predicting the specificity of GalNAc-transferase.
Genetic Diseases, Inborn
Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in GALNT3 Gene: Experience from Southern Turkey
Glioblastoma
Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen.
Glioblastoma
Effects of IGFBP-3 and GalNAc-T14 on proliferation and cell cycle of glioblastoma cells and its mechanism.
Glioblastoma
High expression of GALNT7 promotes invasion and proliferation of glioma cells.
Glioma
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile.
Glioma
High expression of GALNT7 promotes invasion and proliferation of glioma cells.
Glioma
Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Glioma
regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2.
Glomerulonephritis, IGA
Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy.
Glomerulonephritis, IGA
Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy.
Heart Defects, Congenital
Galnt1 is required for normal heart valve development and cardiac function.
Heart Diseases
Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.
Hemorrhagic Fever, Ebola
Site-specific glycosylation of Ebola virus glycoprotein by human polypeptide GalNAc-transferase 1 induces cell adhesion defects.
Herpes Simplex
N-acetylgalactosaminyltransferase activity involved in O-glycosylation of herpes simplex virus type 1 glycoproteins.
Hyperglycemia
GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia.
Hyperostosis
Giantin-knockout models reveal a feedback loop between Golgi function and glycosyltransferase expression.
Hyperostosis
Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Hyperostosis
Phosphatonins: physiological role and pathological changes.
Hyperphosphatemia
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
Hyperphosphatemia
A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
Hyperphosphatemia
A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Hyperphosphatemia
Ablation of the Galnt3 gene leads to low circulating intact Fgf23 concentrations and hyperphosphatemia despite increased Fgf23 expression.
Hyperphosphatemia
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Hyperphosphatemia
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Hyperphosphatemia
Familial Tumoral Calcinosis: From Characterization of a Rare Phenotype to the Pathogenesis of Ectopic Calcification.
Hyperphosphatemia
GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.
Hyperphosphatemia
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
Hyperphosphatemia
Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Hyperphosphatemia
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Hyperphosphatemia
Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.
Hyperphosphatemia
Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium.
Hyperphosphatemia
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Hyperphosphatemia
Phosphatonins: physiological role and pathological changes.
Hyperphosphatemia
Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
Hyperphosphatemia
[Familial tumoral calcinosis with hyperphosphatemia is heterogeneous and associated with mutations in GALNT3 or FGF-23]
Hypertension
Gene environment interaction of GALNT2 and APOE gene with hypertension in the Chinese Han Population.
Hypertension
Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network.
Hypophosphatemia
Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Immune System Diseases
Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.
Infections
Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties.
Infections
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Infections
Influenza A Virus-Induced Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication.
Infections
The C-type lectin receptor MGL senses N-acetylgalactosamine on the unique Staphylococcus aureus ST395 wall teichoic acid.
Infertility
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Infertility, Male
Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Influenza, Human
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Influenza, Human
Influenza A Virus-Induced Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication.
Insulin Resistance
GALNT2 Gene Variant rs4846914 Is Associated with Insulin and Insulin Resistance Depending on BMI in PCOS Patients: a Case-Control Study.
Ischemic Stroke
Triglyceride level modifying functional variants of GALTN2 and MLXIPL in patients with ischaemic stroke.
Keratoconus
Autosomal recessive non-syndromic keratoconus: Homozygous frameshift variant in the candidate novel gene GALNT14.
Leukemia
Expressions of polypeptide: N-acetylgalactosaminyltransferase in leukemia cell lines during 1,25-dihydroxyvitamin D3 induced differentiation.
Leukemia, Lymphocytic, Chronic, B-Cell
GALNT11 as a new molecular marker in chronic lymphocytic leukemia.
Leukopenia
GALNT14 genotype, ?-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.
Liver Diseases
Glycosyltransferases in human blood. II. Study of serum galactosyltransferase and N-acetylgalactosaminyltransferase in patients with liver diseases.
Liver Neoplasms
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Liver Neoplasms
Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.
Lung Neoplasms
Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Lung Neoplasms
Correction to: Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Lung Neoplasms
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Lung Neoplasms
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
Lung Neoplasms
GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
Lung Neoplasms
Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis.
Lung Neoplasms
miR-365b regulates the development of non-small cell lung cancer via GALNT4.
Lung Neoplasms
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
Lung Neoplasms
pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.
Lupus Nephritis
A longitudinal and transancestral analysis of DNA methylation patterns and disease activity in lupus patients.
Lymphatic Metastasis
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Lymphatic Metastasis
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Lymphatic Metastasis
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
Lymphatic Metastasis
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Lymphatic Metastasis
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Lymphatic Metastasis
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Lymphoma
Purification and characterization of UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferase from bovine colostrum and murine lymphoma BW5147 cells.
Lymphoma
[Demonstration of N-acetylgalactosaminyltransferase activity in the murine lymphoma YC8]
Melanoma
Analysis of melanoma cells stably transfected with beta 1,4GalNAc transferase (GM2/GD2 synthase) cDNA: relative glycosyltransferase levels play a dominant role in determining ganglioside expression.
Melanoma
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Melanoma
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Melanoma
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
Melanoma
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.
Melanoma
Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.
Melanoma
Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
Meningioma
Glycosyltransferase activities in human meningiomas. Preliminary results.
Mucopolysaccharidoses
Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
Mucopolysaccharidosis III
Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
Mucopolysaccharidosis III
Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID.
Muscular Dystrophies
Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism.
Myopia
Lack of association with high myopia and the MYP2 locus in the Japanese population by high resolution microsatellite analysis on chromosome 18.
Neoplasm Metastasis
Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Neoplasm Metastasis
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Neoplasm Metastasis
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Neoplasm Metastasis
GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
Neoplasm Metastasis
GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma.
Neoplasm Metastasis
GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment.
Neoplasm Metastasis
GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.
Neoplasm Metastasis
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Neoplasm Metastasis
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
Neoplasm Metastasis
LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity.
Neoplasm Metastasis
LncRNA SNHG7 sponges miR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1.
Neoplasm Metastasis
Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis.
Neoplasm Metastasis
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Neoplasm Metastasis
miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
Neoplasm Metastasis
miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
Neoplasm Metastasis
Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR.
Neoplasm Metastasis
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Neoplasm Metastasis
pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.
Neoplasm Metastasis
regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2.
Neoplasm Metastasis
Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis.
Neoplasm Metastasis
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Neoplasm Metastasis
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Neoplasm Metastasis
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Neoplasm Metastasis
The Role for GALNT14 in the lung metastasis of breast cancer.
Neoplasm Metastasis
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target.
Neoplasms
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Neoplasms
A Pilot Study on the Potential of RNA-Associated to Urinary Vesicles as a Suitable Non-Invasive Source for Diagnostic Purposes in Bladder Cancer.
Neoplasms
Altered expression of different GalNAc?transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Neoplasms
ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
Neoplasms
BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.
Neoplasms
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.
Neoplasms
Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy.
Neoplasms
Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22.
Neoplasms
Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis.
Neoplasms
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Neoplasms
Decreased expression of alpha2,8 sialyltransferase and increased expression of beta1,4 N-acetylgalactosaminyltransferase in gastrointestinal cancers.
Neoplasms
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Neoplasms
Detection of N-acetylgalactosaminyltransferase mRNA which determines expression of Sda blood group carbohydrate structure in human gastrointestinal mucosa and cancer.
Neoplasms
Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Neoplasms
Dual-signal electrochemical sensor for detection of cancer cells by the split primer ligation-triggered catalyzed hairpin assembly.
Neoplasms
Early GalNAc O-Glycosylation: Pushing the Tumor Boundaries.
Neoplasms
Efficient monitoring of enzymatic conjugation reaction by surface-enhanced laser desorption/ionization time of flight mass spectrometry for process optimization.
Neoplasms
Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates.
Neoplasms
Enzymatic large-scale synthesis of MUC6-Tn glycoconjugates for antitumor vaccination.
Neoplasms
ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration.
Neoplasms
Evaluation of GALNT16 polymorphisms to breast cancer risk in Chinese population.
Neoplasms
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (?2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.
Neoplasms
Expression of GalNAc-T3 and its relationships with clinicopathological factors in 61 extrahepatic bile duct carcinomas analyzed using stepwise sections - special reference to its association with lymph node metastases-.
Neoplasms
Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer.
Neoplasms
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Neoplasms
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Neoplasms
Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines.
Neoplasms
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer.
Neoplasms
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma.
Neoplasms
Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.
Neoplasms
Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas.
Neoplasms
GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (??3 cm).
Neoplasms
GalNAc-T6 in the relationship with invasion ability of endometrial carcinomas and prognostic significance.
Neoplasms
GALNT12 is not a major contributor of familial colorectal cancer type X.
Neoplasms
GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
Neoplasms
GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.
Neoplasms
GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Neoplasms
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Neoplasms
GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
Neoplasms
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Neoplasms
GALNT6 suppresses progression of colorectal cancer.
Neoplasms
GALNT9 gene expression is a prognostic marker in neuroblastoma patients.
Neoplasms
Ganglioside biosynthetic gene expression in experimental mouse brain tumors.
Neoplasms
Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Neoplasms
Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
Neoplasms
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
Neoplasms
Glyco-genes change expression in cancer through aberrant methylation.
Neoplasms
Identification of GALNT14 as a novel neuroblastoma predisposition gene.
Neoplasms
Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
Neoplasms
Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis.
Neoplasms
Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase.
Neoplasms
Inherited deleterious variants in GALNT12 are associated with CRC susceptibility.
Neoplasms
Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.
Neoplasms
Isolation of a Golgi-apparatus-enriched fraction from leukaemic cells.
Neoplasms
Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.
Neoplasms
Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Neoplasms
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.
Neoplasms
MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
Neoplasms
miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.
Neoplasms
MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4.
Neoplasms
Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay.
Neoplasms
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Neoplasms
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Neoplasms
Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Neoplasms
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers.
Neoplasms
N-acetylgalactosaminyltransferases in cancer.
Neoplasms
Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Neoplasms
Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.
Neoplasms
Photo-modulation of zinc phthalocyanine-treated breast cancer cell line ZR-75-1 inhibited the normal tumor activity in vitro.
Neoplasms
Poly (A)? transcriptome assessment of ERBB2-induced alterations in breast cell lines.
Neoplasms
Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas.
Neoplasms
Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer.
Neoplasms
Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection.
Neoplasms
Polypeptide-GalNAc-T6 expression predicts better overall survival in patients with colon cancer.
Neoplasms
pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.
Neoplasms
ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.
Neoplasms
Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma.
Neoplasms
Reduced expression of ppGalNAc-T4 promotes proliferation of human breast cancer cells.
Neoplasms
regulation of the invasion and metastasis of human glioma cells by polypeptide N-acetylgalactosaminyltransferase 2.
Neoplasms
Relationship of gangliosides to the structure and function of thyrotropin receptors: their absence on plasma membranes of a thyroid tumor defective in thyrotropin receptor activity.
Neoplasms
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Neoplasms
Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Neoplasms
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Neoplasms
The expression pattern of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetyl-galactosaminyl transferase-3 in squamous cell carcinoma of the esophagus.
Neoplasms
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Neoplasms
The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer.
Neoplasms
The Multiplicity of Polypeptide GalNAc-Transferase: Assays, Inhibitors and Structures.
Neoplasms
The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Neoplasms
The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
Neoplasms
The transcriptional profiling of glycogenes associated with hepatocellular carcinoma metastasis.
Neoplasms
Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells.
Neoplasms
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.
Neoplasms
Treatment of cancer stem cells from human colon adenocarcinoma cell line HT-29 with resveratrol and sulindac induced mesenchymal-endothelial transition rate.
Neoplasms
UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker.
Neoplasms
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.
Neoplasms
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target.
Neoplasms
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Neoplasms
[Prokaryotic expression and antibody preparation of human GALNT3-sol protein].
Neuroblastoma
Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen.
Neuroblastoma
GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Neuroblastoma
GALNT9 gene expression is a prognostic marker in neuroblastoma patients.
Neuroblastoma
Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Neuroblastoma
Identification of GALNT14 as a novel neuroblastoma predisposition gene.
Obesity
GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling.
Oligospermia
Galnt3 deficiency disrupts acrosome formation and leads to oligoasthenoteratozoospermia.
Osteomyelitis
GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis.
Osteomyelitis
Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
Osteoporosis
Association of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture study.
Osteoporosis
Association of genetic polymorphisms of GALNT3 and VDR with osteoporosis in postmenopausal women.
Osteoporosis
Research on correlation between GALNT3 gene and osteoporosis.
Osteosarcoma
High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.
Osteosarcoma
Molecular mechanisms of cadmium-induced FGF23 upregulation in osteoblast-like cells.
Ovarian Neoplasms
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Ovarian Neoplasms
A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies.
Ovarian Neoplasms
BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.
Ovarian Neoplasms
MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
Ovarian Neoplasms
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
Ovarian Neoplasms
Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
Ovarian Neoplasms
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
Ovarian Neoplasms
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
Ovarian Neoplasms
The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
Pancreatic Neoplasms
Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Pancreatic Neoplasms
Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.
Pancreatic Neoplasms
Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth.
Pancreatic Neoplasms
Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival.
Pancreatic Neoplasms
The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer.
Polycystic Ovary Syndrome
GALNT2 Gene Variant rs4846914 Is Associated with Insulin and Insulin Resistance Depending on BMI in PCOS Patients: a Case-Control Study.
polypeptide n-acetylgalactosaminyltransferase deficiency
Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis.
polypeptide n-acetylgalactosaminyltransferase deficiency
Galnt3 deficiency disrupts acrosome formation and leads to oligoasthenoteratozoospermia.
polypeptide n-acetylgalactosaminyltransferase deficiency
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
polypeptide n-acetylgalactosaminyltransferase deficiency
Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents.
Prostatic Neoplasms
Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.
Prostatic Neoplasms
MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4.
Pulmonary Valve Stenosis
Galnt1 is required for normal heart valve development and cardiac function.
Rickets, Hypophosphatemic
Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Rickets, Hypophosphatemic
Molecular cloning of a novel human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T8, and analysis as a candidate autosomal dominant hypophosphatemic rickets (ADHR) gene.
Sarcoma
Glycolipid N-acetylgalactosaminyltransferase activities in normal and Kirsten murine sarcoma virus transformed BALB/c 3T3 cells.
Solitary Pulmonary Nodule
GalNAc-T3 and MUC1, a combined predictor of prognosis and recurrence in solitary pulmonary adenocarcinoma initially diagnosed as malignant solitary pulmonary nodule (??3 cm).
Squamous Cell Carcinoma of Head and Neck
An anti-human ppGalNAcT-2 monoclonal antibody.
Squamous Cell Carcinoma of Head and Neck
Erratum to: Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family.
Squamous Cell Carcinoma of Head and Neck
GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Squamous Cell Carcinoma of Head and Neck
Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma.
Stomach Neoplasms
Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.
Stomach Neoplasms
Detection of cancer cells in peripheral blood of stomach cancer patients using RT-PCR amplification of tumour-specific mRNAs.
Stomach Neoplasms
Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer.
Stomach Neoplasms
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.
Stomach Neoplasms
Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase.
Stomach Neoplasms
Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer.
Stomach Neoplasms
Polypeptide:N-acetylgalactosaminyltransferase activities towards the mucin MUC5AC peptide motif using microsomal preparations of normal and tumoral digestive mucosa.
Stomach Neoplasms
The expression pattern of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 in early gastric carcinoma.
Stroke
Triglyceride level modifying functional variants of GALTN2 and MLXIPL in patients with ischaemic stroke.
Teratoma
Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation.
Thyroid Neoplasms
Expression of Polypeptide N-acetylgalactosaminyl Transferase-3 and Its Association with Clinicopathological Factors in Thyroid Carcinomas.
Urinary Bladder Neoplasms
GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells.
Urinary Bladder Neoplasms
ppGalNAc T1 as a potential novel marker for human bladder cancer.
Uterine Cervical Neoplasms
MicroRNA-214 Suppresses The Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.
Virus Diseases
GALNT3 inhibits NF-?B signaling during influenza A virus infection.
Virus Diseases
Generation of Human Bronchial Epithelial Cell Lines Expressing Inactive Mutants of GALNT3.
Williams Syndrome
A Putative Polypeptide N-Acetylgalactosaminyltransferase/Williams-Beuren Syndrome Chromosome Region 17 (WBSCR17) Regulates Lamellipodium Formation and Macropinocytosis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0025
-
tumoral colon enzyme, MUC5AC peptide
0.0031
-
normal stomach enzyme, MUC5AC peptide
0.0044
-
tumoral stomach and normal colon enzyme, MUC5AC peptide
0.75
purification step 5, Mono S (NaCl)
118
+/-39, MUC1-2GalNAc by mutant GalNAc-T2-D541A, pH7.4
119
+/-24, IgA hinge-4GalNAc by mutant GalNAc-T2-D458H, pH7.4
143
+/-15, MUC1 by mutant GalNAc-T2-D541A, pH7.4
145
+/-21, IgA hinge by mutant GalNAc-T2-D541A, pH7.4
150
+/-6, MUC2 by mutant GalNAc-T2-D458H, pH7.4
236
+/-1, IgA hinge by mutant GalNAc-T2-D458H, pH7.4
273
+/-12, MUC2 by mutant GalNAc-T2-D541A, pH7.4
292
+/-18, MUC2-6GalNAc by mutant GalNAc-T2-D541A, pH7.4
302
+/-17, MUC2-6GalNAc, pH7.4
321
+/-18, IgA hinge, pH7.4
45
+/-13, UDP-GalNAc by mutant GalNAc-T2-D458H, pH7.4
46
+/-12, UDP-GalNAc by mutant GalNAc-T2-D541A, pH7.4
49
+/-5, IgA hinge-4GalNAc by mutant GalNAc-T2-D541A, pH7.4
65
+/-5, UDP-Gal by mutant GalNAc-T2-D458H, pH7.4
69
+/-12, UDP-GalNAc, pH7.4
72
+/-21, MUC1-2GalNAc, pH7.4
83
+/-13, IgA hinge-4GalNAc, pH7.4
85
+/-5, UDP-Gal by mutant GalNAc-T2-D541A, pH7.4
94
+/-5, MUC1 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.005 +/-0.007 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D458H, pH7.4
additional information
0.005 +/-0.007 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D458H, pH7.4
additional information
0.005 +/-0.007 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D458H, pH7.4
additional information
0.005 +/-0.007 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D458H, pH7.4
additional information
0.018 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.018 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.018 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.018 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.018 +/-0.004 micromol/min/ml, MUC1-b, pH7.4
additional information
0.018 +/-0.004 micromol/min/ml, MUC1-b, pH7.4
additional information
0.018 +/-0.004 micromol/min/ml, MUC1-b, pH7.4
additional information
0.018 +/-0.004 micromol/min/ml, MUC1-b, pH7.4
additional information
0.025 +/-0.008 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.025 +/-0.008 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.025 +/-0.008 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.025 +/-0.008 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.028 +/-0.011 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D541A, pH7.4
additional information
0.028 +/-0.011 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D541A, pH7.4
additional information
0.028 +/-0.011 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D541A, pH7.4
additional information
0.028 +/-0.011 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D541A, pH7.4
additional information
0.029 +/-0.007 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.029 +/-0.007 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.029 +/-0.007 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.029 +/-0.007 micromol/min/ml, MUC1-a' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.029 +/-0.008 micromol/min/ml, MUC7, pH7.4
additional information
0.029 +/-0.008 micromol/min/ml, MUC7, pH7.4
additional information
0.029 +/-0.008 micromol/min/ml, MUC7, pH7.4
additional information
0.029 +/-0.008 micromol/min/ml, MUC7, pH7.4
additional information
0.031 +/-0.003 micromol/min/ml, MUC1-a', pH7.4
additional information
0.031 +/-0.003 micromol/min/ml, MUC1-a', pH7.4
additional information
0.031 +/-0.003 micromol/min/ml, MUC1-a', pH7.4
additional information
0.031 +/-0.003 micromol/min/ml, MUC1-a', pH7.4
additional information
0.036 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.036 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.036 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.036 +/-0.003 micromol/min/ml, MUC7, pH7.4
additional information
0.039 +/-0.010 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.039 +/-0.010 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.039 +/-0.010 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.039 +/-0.010 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.046 +/-0.005 micromol/min/ml, MUC7 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.005 micromol/min/ml, MUC7 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.005 micromol/min/ml, MUC7 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.005 micromol/min/ml, MUC7 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.006 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.046 +/-0.006 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.046 +/-0.006 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.046 +/-0.006 micromol/min/ml, MUC1-2GalNAC, pH7.4
additional information
0.046 +/-0.009 micromol/min/ml, MUC2-6GalNAc by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.009 micromol/min/ml, MUC2-6GalNAc by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.009 micromol/min/ml, MUC2-6GalNAc by mutant GalNAc-T2-D541A, pH7.4
additional information
0.046 +/-0.009 micromol/min/ml, MUC2-6GalNAc by mutant GalNAc-T2-D541A, pH7.4
additional information
0.047 +/-0.011 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D458H, pH7.4
additional information
0.047 +/-0.011 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D458H, pH7.4
additional information
0.047 +/-0.011 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D458H, pH7.4
additional information
0.047 +/-0.011 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D458H, pH7.4
additional information
0.051 +/-0.006 micromol/min/ml, hCG-beta, pH7.4
additional information
0.051 +/-0.006 micromol/min/ml, hCG-beta, pH7.4
additional information
0.051 +/-0.006 micromol/min/ml, hCG-beta, pH7.4
additional information
0.051 +/-0.006 micromol/min/ml, hCG-beta, pH7.4
additional information
0.053 +/-0.010 micromol/min/ml, MUC7 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.053 +/-0.010 micromol/min/ml, MUC7 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.053 +/-0.010 micromol/min/ml, MUC7 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.053 +/-0.010 micromol/min/ml, MUC7 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.054 +/-0.001 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D458H, pH7.4
additional information
0.054 +/-0.001 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D458H, pH7.4
additional information
0.054 +/-0.001 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D458H, pH7.4
additional information
0.054 +/-0.001 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D458H, pH7.4
additional information
0.055 +/-0.008 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D541A, pH7.4
additional information
0.055 +/-0.008 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D541A, pH7.4
additional information
0.055 +/-0.008 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D541A, pH7.4
additional information
0.055 +/-0.008 micromol/min/ml, MUC1-2GalNaC by mutant GalNAc-T2-D541A, pH7.4
additional information
0.062 +/-0.010 micromol/min/ml, MUC2-6GalNAc, pH7.4
additional information
0.062 +/-0.010 micromol/min/ml, MUC2-6GalNAc, pH7.4
additional information
0.062 +/-0.010 micromol/min/ml, MUC2-6GalNAc, pH7.4
additional information
0.062 +/-0.010 micromol/min/ml, MUC2-6GalNAc, pH7.4
additional information
0.065 +/-0.007 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D541A, pH7.4
additional information
0.065 +/-0.007 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D541A, pH7.4
additional information
0.065 +/-0.007 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D541A, pH7.4
additional information
0.065 +/-0.007 micromol/min/ml, hCG-beta by mutant GalNAc-T2-D541A, pH7.4
additional information
0.066 +/-0.008 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D541A, pH7.4
additional information
0.066 +/-0.008 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D541A, pH7.4
additional information
0.066 +/-0.008 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D541A, pH7.4
additional information
0.066 +/-0.008 micromol/min/ml, erythropoitin T by mutant GalNAc-T2-D541A, pH7.4
additional information
0.074 +/-0.005 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.074 +/-0.005 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.074 +/-0.005 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.074 +/-0.005 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.076 +/-0.003 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.076 +/-0.003 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.076 +/-0.003 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.076 +/-0.003 micromol/min/ml, erythropoitin T, pH7.4
additional information
0.085 +/-0.003 micromol/min/ml, MUC1-a, pH7.4
additional information
0.085 +/-0.003 micromol/min/ml, MUC1-a, pH7.4
additional information
0.085 +/-0.003 micromol/min/ml, MUC1-a, pH7.4
additional information
0.085 +/-0.003 micromol/min/ml, MUC1-a, pH7.4
additional information
0.086 +/-0.007 micromol/min/ml, MUC1-a, pH7.4
additional information
0.086 +/-0.007 micromol/min/ml, MUC1-a, pH7.4
additional information
0.086 +/-0.007 micromol/min/ml, MUC1-a, pH7.4
additional information
0.086 +/-0.007 micromol/min/ml, MUC1-a, pH7.4
additional information
0.087 +/-0.006 micromol/min/ml, MUC1-b', pH7.4
additional information
0.087 +/-0.006 micromol/min/ml, MUC1-b', pH7.4
additional information
0.087 +/-0.006 micromol/min/ml, MUC1-b', pH7.4
additional information
0.087 +/-0.006 micromol/min/ml, MUC1-b', pH7.4
additional information
0.094 +/-0.008 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.094 +/-0.008 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.094 +/-0.008 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.094 +/-0.008 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D458H, pH7.4
additional information
0.097 +/-0.002 micromol/min/ml, MUC1, pH7.4
additional information
0.097 +/-0.002 micromol/min/ml, MUC1, pH7.4
additional information
0.097 +/-0.002 micromol/min/ml, MUC1, pH7.4
additional information
0.097 +/-0.002 micromol/min/ml, MUC1, pH7.4
additional information
0.108 +/-0.002 micromol/min/ml, OSM fragment, pH7.4
additional information
0.108 +/-0.002 micromol/min/ml, OSM fragment, pH7.4
additional information
0.108 +/-0.002 micromol/min/ml, OSM fragment, pH7.4
additional information
0.108 +/-0.002 micromol/min/ml, OSM fragment, pH7.4
additional information
0.121 +/-0.013 micromol/min/ml, MUC1 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.121 +/-0.013 micromol/min/ml, MUC1 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.121 +/-0.013 micromol/min/ml, MUC1 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.121 +/-0.013 micromol/min/ml, MUC1 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.122 +/-0.007 micromol/min/ml, MUC1, pH7.4
additional information
0.122 +/-0.007 micromol/min/ml, MUC1, pH7.4
additional information
0.122 +/-0.007 micromol/min/ml, MUC1, pH7.4
additional information
0.122 +/-0.007 micromol/min/ml, MUC1, pH7.4
additional information
0.125 +/-0.003 micromol/min/ml, MUC2, pH7.4
additional information
0.125 +/-0.003 micromol/min/ml, MUC2, pH7.4
additional information
0.125 +/-0.003 micromol/min/ml, MUC2, pH7.4
additional information
0.125 +/-0.003 micromol/min/ml, MUC2, pH7.4
additional information
0.142 +/-0.005 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D541A, pH7.4
additional information
0.142 +/-0.005 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D541A, pH7.4
additional information
0.142 +/-0.005 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D541A, pH7.4
additional information
0.142 +/-0.005 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D541A, pH7.4
additional information
0.151 +/-0.012 micromol/min/ml, MUC1 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.151 +/-0.012 micromol/min/ml, MUC1 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.151 +/-0.012 micromol/min/ml, MUC1 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.151 +/-0.012 micromol/min/ml, MUC1 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.158 +/-0.010 micromol/min/ml, MUC1, pH7.4
additional information
0.158 +/-0.010 micromol/min/ml, MUC1, pH7.4
additional information
0.158 +/-0.010 micromol/min/ml, MUC1, pH7.4
additional information
0.158 +/-0.010 micromol/min/ml, MUC1, pH7.4
additional information
0.161 +/-0.005 micromol/min/ml, IgA hinge, pH7.4
additional information
0.161 +/-0.005 micromol/min/ml, IgA hinge, pH7.4
additional information
0.161 +/-0.005 micromol/min/ml, IgA hinge, pH7.4
additional information
0.161 +/-0.005 micromol/min/ml, IgA hinge, pH7.4
additional information
0.164 +/-0.007 micromol/min/ml, MUC2 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.164 +/-0.007 micromol/min/ml, MUC2 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.164 +/-0.007 micromol/min/ml, MUC2 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.164 +/-0.007 micromol/min/ml, MUC2 by mutant GalNAc-T2-D458H, pH7.4
additional information
0.165 +/-0.013 micromol/min/ml, MUC2 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.165 +/-0.013 micromol/min/ml, MUC2 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.165 +/-0.013 micromol/min/ml, MUC2 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.165 +/-0.013 micromol/min/ml, MUC2 by mutant GalNAc-T2-D541A, pH7.4
additional information
0.185 +/-0.006 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D458H, pH7.4
additional information
0.185 +/-0.006 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D458H, pH7.4
additional information
0.185 +/-0.006 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D458H, pH7.4
additional information
0.185 +/-0.006 micromol/min/ml, IgA hinge by mutant GalNAc-T2-D458H, pH7.4
additional information
0.224 +/-0.002 micromol/min/ml, IgA hinge, pH7.4
additional information
0.224 +/-0.002 micromol/min/ml, IgA hinge, pH7.4
additional information
0.224 +/-0.002 micromol/min/ml, IgA hinge, pH7.4
additional information
0.224 +/-0.002 micromol/min/ml, IgA hinge, pH7.4
additional information
0.281 +/-0.013 micromol/min/ml, IgA hinge, pH7.4
additional information
0.281 +/-0.013 micromol/min/ml, IgA hinge, pH7.4
additional information
0.281 +/-0.013 micromol/min/ml, IgA hinge, pH7.4
additional information
0.281 +/-0.013 micromol/min/ml, IgA hinge, pH7.4
additional information
0.283 +/-0.010 micromol/min/ml, MUC2, pH7.4
additional information
0.283 +/-0.010 micromol/min/ml, MUC2, pH7.4
additional information
0.283 +/-0.010 micromol/min/ml, MUC2, pH7.4
additional information
0.283 +/-0.010 micromol/min/ml, MUC2, pH7.4
additional information
128 +/-0.007 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D541A, pH7.4
additional information
128 +/-0.007 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D541A, pH7.4
additional information
128 +/-0.007 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D541A, pH7.4
additional information
128 +/-0.007 micromol/min/ml, MUC1-b' by mutant GalNAc-T2-D541A, pH7.4
additional information
152 +/-0.018 micromol/min/ml, MUC2, pH7.4
additional information
152 +/-0.018 micromol/min/ml, MUC2, pH7.4
additional information
152 +/-0.018 micromol/min/ml, MUC2, pH7.4
additional information
152 +/-0.018 micromol/min/ml, MUC2, pH7.4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Soerensen, T.; White, T.; Wandall, H.H.; Kristensen, A.K.; Roepstorff, P.; Clausen, H.
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. Identification and separation of two distinct transferase activities
J. Biol. Chem.
270
24166-24173
1995
Homo sapiens, Ovis sp., Rattus norvegicus, Sus scrofa
brenda
Wandall, H.H.; Hassan, H.; Mirgorodskaya, E.; Kristensen, A.K.; Roepstorff, P.; Bennett, E.P.; Nielsen, P.A.; Hollingsworth, M.A.; Burchell, J.; Taylor-Papadimitriou, J.; Clausen, H.
Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3
J. Biol. Chem.
272
23503-23514
1997
Homo sapiens
brenda
Bennett, E.P.; Hassan, H.; Hollingsworth, M.A.; Clausen, H.
A novel human UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T7, with specificity for partial GalNAc-glycosylated acceptor substrates
FEBS Lett.
460
226-230
1999
Homo sapiens (Q86SF2), Homo sapiens
brenda
Toba, S.; Tenno, M.; Konishi, M.; Mikami, T.; Itoh, N.; Kurosaka, A.
Brain-specific expression of a novel human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T9)
Biochim. Biophys. Acta
1493
264-268
2000
Homo sapiens
brenda
Wang, H.; Tachibana, K.; Zhang, Y.; Iwasaki, H.; Kameyama, A.; Cheng, L.; Guo, J.; Hiruma, T.; Togayachi, A.; Kudo, T.; Kikuchi, N.; Narimatsu, H.
Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14
Biochem. Biophys. Res. Commun.
300
738-744
2003
Homo sapiens
brenda
Zhang, Y.; Iwasaki, H.; Wang, H.; Kudo, T.; Kalka, T.B.; Hennet, T.; Kubota, T.; Cheng, L.; Inaba, N.; Gotoh, M.; Togayachi, A.; Guo, J.; Hisatomi, H.; Nakajima, K.; Nishihara, S.; Nakamura, M.; Marth, J.D.; Narimatsu, H.
Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen
J. Biol. Chem.
278
573-584
2003
Homo sapiens, Homo sapiens (Q8IUC8), Mus musculus
brenda
Hanisch, F.G.; Reis, C.A.; Clausen, H.; Paulsen, H.
Evidence for glycosylation-dependent activities of polypeptide N-acetylgalactosaminyltransferases rGalNAc-T2 and -T4 on mucin glycopeptides
Glycobiology
11
731-740
2001
Homo sapiens
brenda
Iwasaki, H.; Zhang, Y.; Tachibana, K.; Gotoh, M.; Kikuchi, N.; Kwon, Y.D.; Togayachi, A.; Kudo, T.; Kubota, T.; Narimatsu, H.
Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2
J. Biol. Chem.
278
5613-5621
2003
Homo sapiens
brenda
Hennebicq, S.; Tetaert, D.; Soudan, B.; Briand, G.; Richet, C.; Demeyer, D.; Gagnon, J.; Petillot, Y.; Degand, P.
Polypeptide:N-acetylgalactosaminyltransferase activities towards the mucin MUC5AC peptide motif using microsomal preparations of normal and tumoral digestive mucosa
Biochimie
80
69-73
1998
Homo sapiens
brenda
Takeuchi, H.; Kato, K.; Hassan, H.; Clausen, H.; Irimura, T.
O-GalNAc incorporation into a cluster acceptor site of three consecutive threonines. Distinct specificity of GalNAc-transferase isoforms
Eur. J. Biochem.
269
6173-6183
2002
Homo sapiens
brenda
Katao, K.; Takeuchi, H.; Miyahara, N.; Kanoh, A.; Hassan, H.; Clausen, H.; Irimura, T.
Distinct orders of GalNAc incorporation into a peptide with consecutive threonines
Biochem. Biophys. Res. Commun.
287
110-115
2001
Homo sapiens
brenda
Iida, S.I.; Takeuchi, H.; Kato, K.; Yamamoto, K.; Irimura, T.
Order and maximum incorporation of N-acetyl-D-galactosamine into threonine residues of MUC2 core peptide with microsome fraction of human-colon-carcinoma LS174T cells
Biochem. J.
347
535-542
2000
Homo sapiens
brenda
Nishimaori, I.; Fontenot, J.D.; Hollingsworth, M.A.
N-Acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts
Cancer Res.
54
3738-3744
1994
Homo sapiens
brenda
Marcos, N.T.; Cruz, A.; Silva, F.; Almeida, R.; David, L.; Mandel, U.; Clausen, H.; von Mensdorff-Pouilly, S.; Reis, C.A.
Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines
J. Histochem. Cytochem.
51
761-771
2003
Homo sapiens
brenda
Nakamura, N.; Toba, S.; Hirai, M.; Morishita, S.; Mikami, T.; Konishi, M.; Itoh, N.; Kurosaka, A.
Cloning and expression of a brain-specific putative UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase gene
Biol. Pharm. Bull.
28
429-433
2005
Rattus norvegicus, Homo sapiens (Q9HCQ5), Homo sapiens
brenda
Guo, J.M.; Zhang, Y.; Cheng, L.; Iwasaki, H.; Wang, H.; Kubota, T.; Tachibana, K.; Narimatsu, H.
Molecular cloning; characterization of a novel member of the UDP-GalNAc polypeptide N-acetylgalactosaminyltransferase family,ppGalNAc-T12
FEBS Lett.
26297
1-8
2002
Homo sapiens (Q8IXK2)
-
brenda
Cheng, L.; Tachibana, K.; Iwasaki, H.; Kameyama, A.; Zhang, Y.; Kubota, T.; Hiruma, T.; Kudo, T.; Guo, J.M.; Narimatsu, H.
Characterization of a novel human UDP-GalNAc transferase, pp-GalNAc-T15
FEBS Lett.
566
17-24
2004
Homo sapiens (Q10471), Homo sapiens (Q7Z4T8), Homo sapiens
brenda
White, T.; Bennett, E.P.; Takio, K.; Sorensen, T.; Bonding, N.; Clausen, H.
Purification and cDNA cloning of a human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase
J. Biol. Chem.
270
24156-24165
1995
Homo sapiens (Q10471), Homo sapiens (Q10472), Homo sapiens
brenda
Bennett, E.P.; Hassan, H.; Clausen, H.
cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosaminyltransferase
J. Biol. Chem.
271
17006-17012
1996
Homo sapiens (Q14435), Homo sapiens
brenda
Bennett, R.P.; Hassan, H.; Mandel, U.; Mirgorodskaya, E.; et al.
Cloning of human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat
J. Biol. Chem.
273
30472-30481
1998
Homo sapiens (Q10471), Homo sapiens (Q10472), Homo sapiens (Q8N4A0), Homo sapiens
brenda
Bennett, E.P.; Hassan, H.; Mandel, U.; Hollingsworth, M.A.; Akisawa, N.; Ikematsu, Y.; Merkx, G.; van Kessel, A.G.; Olofsson, S.; Clausen, H.
Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6
J. Biol. Chem.
274
25362-25370
1999
Homo sapiens (Q8NCL4), Homo sapiens
brenda
Sschwientek, T.; Bennett, E.P.; Flores, C.; et al.
Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans and mammals
J. Biol. Chem.
277
22623-22638
2002
Homo sapiens (Q8NCW6), Homo sapiens
brenda
Fritz, T.A.; Raman, J.; Tabak, L.A.
Dynamic association between the catalytic and lectin domains of human UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-2
J. Biol. Chem.
281
8613-8619
2006
Homo sapiens
brenda
Brooks, S.A.; Carter, T.M.; Bennett, E.P.; Clausen, H.; Mandel, U.
Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer
Acta Histochem.
109
273-284
2007
Homo sapiens (Q10471), Homo sapiens (Q10472), Homo sapiens (Q14435), Homo sapiens (Q8N4A0), Homo sapiens (Q8NCL4)
brenda
Wandall, H.H.; Irazoqui, F.; Tarp, M.A.; Bennett, E.P.; Mandel, U.; Takeuchi, H.; Kato, K.; Irimura, T.; Suryanarayanan, G.; Hollingsworth, M.A.; Clausen, H.
The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation
Glycobiology
17
374-387
2007
Homo sapiens (Q10471), Homo sapiens (Q10472), Homo sapiens (Q8N4A0), Homo sapiens (Q8NCW6)
brenda
Gerken, T.A.; Hagen, K.G.; Jamison, O.
Conservation of peptide acceptor preferences between Drosophila and mammalian polypeptide-GalNAc transferase orthologue pairs
Glycobiology
18
861-870
2008
Bos taurus (Q07537), Homo sapiens (Q10471), Drosophila melanogaster (Q6WV17), Drosophila melanogaster (Q6WV19)
brenda
Raman, J.; Fritz, T.A.; Gerken, T.A.; Jamison, O.; Live, D.; Liu, M.; Tabak, L.A.
The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase function in concert to direct glycosylation site selection
J. Biol. Chem.
283
22942-22951
2008
Homo sapiens
brenda
Milac, A.L.; Buchete, N.V.; Fritz, T.A.; Hummer, G.; Tabak, L.A.
Substrate-induced conformational changes and dynamics of UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase-2
J. Mol. Biol.
373
439-451
2007
Homo sapiens (Q10471)
brenda
Wu, C.; Wang, Y.; Zou, M.; Shan, Y.; Yao, G.; Wei, P.; Chen, G.; Wang, J.; Xu, D.
Prokaryotic expression, purification, and production of polyclonal antibody against human polypeptide N-acetylgalactosaminyltransferase 14
Protein Expr. Purif.
56
1-7
2007
Homo sapiens (Q96FL9), Homo sapiens
brenda
Brockhausen, I.; Dowler, T.; Paulsen, H.
Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2
Biochim. Biophys. Acta
1790
1244-1257
2009
Bos taurus, Homo sapiens (Q10472)
brenda
Perrine, C.L.; Ganguli, A.; Wu, P.; Bertozzi, C.R.; Fritz, T.A.; Raman, J.; Tabak, L.A.; Gerken, T.A.
Glycopeptide-preferring polypeptide GalNAc transferase 10 (ppGalNAc T10), involved in mucin-type O-glycosylation, has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2
J. Biol. Chem.
284
20387-20397
2009
Bos taurus, Homo sapiens
brenda
Gomes, J.; Marcos, N.T.; Berois, N.; Osinaga, E.; Magalhaes, A.; Pinto-de-Sousa, J.; Almeida, R.; Gaertner, F.; Reis, C.A.
Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma
J. Histochem. Cytochem.
57
79-86
2009
Homo sapiens
brenda
Guda, K.; Moinova, H.; He, J.; Jamison, O.; Ravi, L.; Natale, L.; Lutterbaugh, J.; Lawrence, E.; Lewis, S.; Willson, J.K.; Lowe, J.B.; Wiesner, G.L.; Parmigiani, G.; Barnholtz-Sloan, J.; Dawson, D.W.; Velculescu, V.E.; Kinzler, K.W.; Papadopoulos, N.; Vogelstein, B.; Willis, J.; Gerken, T.A.; Markowitz,
Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers
Proc. Natl. Acad. Sci. USA
106
12921-12925
2009
Homo sapiens (Q8IXK2), Homo sapiens
brenda
Zlocowski, N.; Sendra, V.G.; Lorenz, V.; Villarreal, M.A.; Jorge, A.; Nunez, Y.; Bennett, E.P.; Clausen, H.; Nores, G.A.; Irazoqui, F.J.
Catalytic and glycan-binding abilities of ppGalNAc-T2 are regulated by acetylation
Biochem. Biophys. Res. Commun.
410
140-145
2011
Homo sapiens
brenda
Schjoldager, K.T.; Clausen, H.
Site-specific protein O-glycosylation modulates proprotein processing - Deciphering specific functions of the large polypeptide GalNAc-transferase gene family
Biochim. Biophys. Acta
1820
2079-2094
2012
Homo sapiens
brenda
Yoshimura, Y.; Nudelman, A.S.; Levery, S.B.; Wandall, H.H.; Bennett, E.P.; Hindsgaul, O.; Clausen, H.; Nishimura, S.
Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates
Glycobiology
22
429-438
2012
Homo sapiens
brenda
Li, X.; Wang, J.; Li, W.; Xu, Y.; Shao, D.; Xie, Y.; Xie, W.; Kubota, T.; Narimatsu, H.; Zhang, Y.
Characterization of ppGalNAc-T18, a member of the vertebrate-specific Y subfamily of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases
Glycobiology
22
602-615
2012
Homo sapiens (Q58A54)
brenda
Raman, J.; Guan, Y.; Perrine, C.L.; Gerken, T.A.; Tabak, L.A.
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases: completion of the family tree
Glycobiology
22
768-777
2012
Homo sapiens
brenda
Hua, D.; Shen, L.; Xu, L.; Jiang, Z.; Zhou, Y.; Yue, A.; Zou, S.; Cheng, Z.; Wu, S.
Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer
Int. J. Mol. Med.
30
1267-1274
2012
Homo sapiens
brenda
Park, J.H.; Katagiri, T.; Chung, S.; Kijima, K.; Nakamura, Y.
Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin
Neoplasia
13
320-326
2011
Homo sapiens
brenda
Schjoldager, K.; Vakhrushev, S.; Kong, Y.; Steentoft, C.; Nudelman, A.; Pedersen, N.; Wandall, H.; Mandel, U.; Bennett, E.; Levery, S.; Clausen, H.
Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells
Proc. Natl. Acad. Sci. USA
109
9893-9898
2012
Homo sapiens
brenda
Lira-Navarrete, E.; Iglesias-Fernandez, J.; Zandberg, W.F.; Companon, I.; Kong, Y.; Corzana, F.; Pinto, B.M.; Clausen, H.; Peregrina, J.M.; Vocadlo, D.J.; Rovira, C.; Hurtado-Guerrero, R.
Substrate-guided front-face reaction revealed by combined structural snapshots and metadynamics for the polypeptide N-acetylgalactosaminyltransferase 2
Angew. Chem. Int. Ed. Engl.
53
8206-8210
2014
Homo sapiens
brenda
Irazoqui, F.; Zlocowski, N.; Lorenz, V.; Bennett, E.; Clausen, H.; Nores, G.
An acetylation site in lectin domain modulates the biological activity of polypeptide GalNAc-transferase-2
Biol. Chem.
394
69-77
2013
Homo sapiens
brenda
Kong, Y.; Joshi, H.J.; Schjoldager, K.T.; Madsen, T.D.; Gerken, T.A.; Vester-Christensen, M.B.; Wandall, H.H.; Bennett, E.P.; Levery, S.B.; Vakhrushev, S.Y.; Clausen, H.
Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis
Glycobiology
25
55-65
2015
Homo sapiens
brenda
Gerken, T.A.; Revoredo, L.; Thome, J.J.; Tabak, L.A.; Vester-Christensen, M.B.; Clausen, H.; Gahlay, G.K.; Jarvis, D.L.; Johnson, R.W.; Moniz, H.A.; Moremen, K.
The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation
J. Biol. Chem.
288
19900-19914
2013
Bos taurus, Homo sapiens
brenda
Song, L.; Bachert, C.; Schjoldager, K.T.; Clausen, H.; Linstedt, A.D.
Development of isoform-specific sensors of polypeptide GalNAc-transferase activity
J. Biol. Chem.
289
30556-30566
2014
Homo sapiens
brenda
Wang, R.; Yu, C.; Zhao, D.; Wu, M.; Yang, Z.
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13
Oncol. Rep.
30
667-676
2013
Homo sapiens
brenda
Wang, Z.Q.; Bachvarova, M.; Morin, C.; Plante, M.; Gregoire, J.; Renaud, M.C.; Sebastianelli, A.; Bachvarov, D.
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation
Oncotarget
5
544-560
2014
Homo sapiens
brenda
Gomez, H.; Rojas, R.; Patel, D.; Tabak, L.A.; Lluch, J.M.; Masgrau, L.
A computational and experimental study of O-glycosylation. Catalysis by human UDP-GalNAc polypeptide:GalNAc transferase-T2
Org. Biomol. Chem.
12
2645-2655
2014
Homo sapiens (Q10471), Homo sapiens
brenda
Mochizuki, Y.; Ito, K.; Izumi, H.; Kohno, K.; Amano, J.
Expression of polypeptide N-acetylgalactosaminyl transferase-3 and its association with clinicopathological factors in thyroid carcinomas
Thyroid
23
1553-1560
2013
Homo sapiens (Q14435), Homo sapiens
brenda
Yu, C.; Liang, L.; Yin, Y.
Structural basis of carbohydrate transfer activity of UDP-GalNAc Polypeptide N-acetylgalactosaminyltransferase 7
Biochem. Biophys. Res. Commun.
510
266-271
2019
Homo sapiens (Q86SF2)
brenda
Shan, A.; Lu, J.; Xu, Z.; Li, X.; Xu, Y.; Li, W.; Liu, F.; Yang, F.; Sato, T.; Narimatsu, H.; Zhang, Y.
Polypeptide N-acetylgalactosaminyltransferase 18 non-catalytically regulates the ER homeostasis and O-glycosylation
Biochim. Biophys. Acta
1863
870-882
2019
Homo sapiens (Q6P9A2)
brenda
Lackman, J.J.; Goth, C.K.; Halim, A.; Vakhrushev, S.Y.; Clausen, H.; Petaejae-Repo, U.E.
Site-specific O-glycosylation of N-terminal serine residues by polypeptide GalNAc-transferase 2 modulates human delta-opioid receptor turnover at the plasma membrane
Cell. Signal.
42
184-193
2018
Homo sapiens (Q10471), Homo sapiens
brenda
Yan, X.; Lu, J.; Zou, X.; Zhang, S.; Cui, Y.; Zhou, L.; Liu, F.; Shan, A.; Lu, J.; Zheng, M.; Feng, B.; Zhang, Y.
The polypeptide N-acetylgalactosaminyltransferase 4 exhibits stage-dependent expression in colorectal cancer and affects tumorigenesis, invasion and differentiation
FEBS J.
285
3041-3055
2018
Homo sapiens (Q8N4A0), Homo sapiens
brenda
Choi, J.; Wagner, L.J.S.; Timmermans, S.B.P.E.; Malaker, S.A.; Schumann, B.; Gray, M.A.; Debets, M.F.; Takashima, M.; Gehring, J.; Bertozzi, C.R.
Engineering orthogonal polypeptide GalNAc-transferase and UDP-sugar pairs
J. Am. Chem. Soc.
141
13442-13453
2019
Homo sapiens (Q10471), Homo sapiens
brenda
Goth, C.K.; Tuhkanen, H.E.; Khan, H.; Lackman, J.J.; Wang, S.; Narimatsu, Y.; Hansen, L.H.; Overall, C.M.; Clausen, H.; Schjoldager, K.T.; Petaejae-Repo, U.E.
Site-specific O-glycosylation by polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-transferase T2) co-regulates beta1-adrenergic receptor N-terminal cleavage
J. Biol. Chem.
292
4714-4726
2017
Homo sapiens (Q10471)
brenda
Hintze, J.; Ye, Z.; Narimatsu, Y.; Madsen, T.D.; Joshi, H.J.; Goth, C.K.; Linstedt, A.; Bachert, C.; Mandel, U.; Bennett, E.P.; Vakhrushev, S.Y.; Schjoldager, K.T.
Probing the contribution of individual polypeptide GalNAc-transferase isoforms to the O-glycoproteome by inducible expression in isogenic cell lines
J. Biol. Chem.
293
19064-19077
2018
Homo sapiens (Q10471), Homo sapiens (Q8NCW6)
brenda
Simon, E.J.; Linstedt, A.D.
Site-specific glycosylation of Ebola virus glycoprotein by human polypeptide GalNAc-transferase 1 induces cell adhesion defects
J. Biol. Chem.
293
19866-19873
2018
Homo sapiens (Q10472), Homo sapiens
brenda